Biotech loj hlob Tshuag TG Kev Kho Mob (TGTX) tau txais kev pom zoo los ntawm FDA rau nws cov tshuaj ntau yam sclerosis nyob rau lub Kaum Ob Hlis, teeb tsa kev ua ntej muaj zog uas tau ntxiv 80% txog rau xyoo no. Koj tuaj yeem pom cov teeb meem kev coj noj coj ua zoo tshaj no nrog rau IBD Stock Screener.
X
TG Therapeutics yuav muag Briumvi rau cov kws kho mob raws li IV infusion nyob rau hauv kev kho mob ntawm relapsing cov ntaub ntawv ntawm ntau yam sclerosis thiab active theem nrab cov mob. Lub sij hawm infusion ib-teev yog ib qho kev txhim kho dua li ob-teev kev xav tau ntawm cov tshuaj laus.
Cov khoom xyaw muaj cov khoom siv hluavtaws uas ua haujlwm zoo li tib neeg cov tshuaj tiv thaiv kab mob, txhawb kev tiv thaiv kab mob. Nws ua rau muaj cov tshuaj lom neeg lom neeg, suav nrog cytotoxicity, ua rau kev puas tsuaj ntawm cov hlwb tsis zoo.
Briumvi kuj ua haujlwm yam tsis muaj cov piam thaj molecules ib txwm qhia ntawm cov tshuaj tiv thaiv. Los ntawm cov txheej txheem no, cov protein txhawb kev tiv thaiv kab mob zoo dua.
FDA pom zoo ua raws li ua tiav kev sim tshuaj uas tau pom cov txiaj ntsig zoo thiab qib kev nyab xeeb siab. Ntau tus neeg mob sclerosis nrog tsawg kawg ib qho rov qab los hauv xyoo dhau los tau koom nrog peb qhov kev sim.
Cov tshuaj tiv thaiv kab mob tsom rau ib qho tshwj xeeb membrane protein ntawm B-hlwb uas tswj cov receptors ntawm lymphocytes. Los ntawm receptors, B-hlwb khi cov proteins thiab nres qee yam haujlwm uas yuav ua rau muaj kev phom sij. Txawm li cas los xij, kev ua haujlwm tsis zoo ntawm B-hlwb tuaj yeem ua rau muaj kab mob autoimmune.
Briumvi kuj kho cov tsos mob cuam tshuam nrog kev kho mob cais tawm xws li ob lub qhov muag thiab loog loog.
TG Therapeutics tau koom tes nrog Samsung Biologics rau kev cog lus kev tsim kho, kev tsim khoom, thiab kev pabcuam kuaj mob.
Kev loj hlob Tshuag nce 80% ntawm FDA pom zoo
Shares ntawm cov khoom lag luam loj hlob no tau nce siab tom qab cov xov xwm thiab tam sim no txuas ntxiv saum toj no muas point ntawm 9.80.
New York-based biotech yog koom nrog Medical-Biomed / Biotech pawg, uas nyob qib 18 ntawm IBD's 197 pawg kev lag luam. TGTX Tshuag muaj zoo meej 99 txheeb ze zog thiab kev ntsuam xyuas sib xyaw.
Lub biotech tsis tau txais txiaj ntsig tau ntau xyoo, uas yog ib txwm muaj nrog cov haujlwm no nyiaj txiag tshaib plab. Txawm li cas los xij, nws tau kwv yees tias yuav poob tsuas yog 18 xees ib feem hauv 2023, qhov kev txhim kho loj tshaj 2022 qhov poob 48 xees. Tsis tas li ntawd, HC Wainwright cov kws tshuaj ntsuam xyuas kwv yees 2023 muag ntawm $ 46.1 lab, nce mus rau kev noj qab haus huv $ 558 lab hauv 2028.
Mutual funds muaj 52% ntawm cov khoom lag luam zoo. SPDR S&P Biotech ETF (XBI) thiab Vanguard Small Cap ETF (VB) kuj tuav TGTX Tshuag.
Thov ua raws li VRamakrishnan @IBD_VRamakrishnan kom paub ntau ntxiv txog cov khoom lag luam loj hlob.
KOJ UA LI CAS:
Kev Lag Luam Kev Lag Luam Kev Lag Luam Rau 2023: Kev Sib Tw Abound
Tau Txais IBD Cov Ntawv Xov Xwm Dawb: Ua Lag Luam Prep | Tech Qhia | Kev Ua Lag Luam Li Cas
YUAV UA LI CAS YOG SLIM? Yog Tias Koj Xav Pom Cov Txiaj Ntsim Zoo Tom Qab, Rov Tuaj Zoo Dua
Live IBD: Kawm Thiab Tshawb Kev Loj Hlob Cov Lus Cog Tseg Nrog Cov Pros
Tau qhov twg los: https://www.investors.com/research/growth-stock-surges-after-fda-approval-for-autoimmune-disease-boosts-shares-of-biomed-company/?src=A00220&yptr=yahoo